Revista clínica española
-
Revista clínica española · Aug 2021
Case Reports[Public healthcare expenditure and COVID-19 mortality in Spain and in Europe].
To analyze the association between public health expenditure per capita and the mortality rate due to COVID-19 in Europe and Spain. ⋯ The available evidence does not support association between «low» public healthcare expenditure and the poor outcomes observed in Spain during the COVID-19 pandemic. Increased funding for the Spanish National Health System should be earmarked for structural reforms to increase its social efficiency.
-
Revista clínica española · Aug 2021
[Telemedicine, ethics, and law in times of COVID-19. A look towards the future].
The health emergency in Spain caused by COVID-19 was of such a magnitude that on March 14, 2020, a state of alarm was declared that lasted for more than three months. This ongoing pandemic has affected a vast number of people. ⋯ Telemedicine lacks specific regulations and has loopholes that leave physicians with a considerable degree of insecurity. This article analyzes the limits, precautions, and legal standards of the use of telemedicine.
-
Revista clínica española · Jun 2021
Effect of in-hospital glycemic variability on mortality in patients with diabetes.
The aim of this study was to evaluate the impact of mean blood glucose (MBG) and glycaemic variability (GV) during hospitalisation on mortality after discharge. ⋯ The simultaneous presence of a high MBG level and CV constitutes a powerful tool for stratifying mortality risk after hospital discharge.
-
Revista clínica española · Jun 2021
Prevalence of hypertrophic cardiomyopathy in a large sample of the Spanish working population.
To date, in Spain, there are no studies that have evaluated the prevalence of hypertrophic cardiomyopathy in the general population. The aim of this study was to assess the prevalence of hypertrophic cardiomyopathy in a large sample of the working population of Spain. ⋯ In our sample of the working population in Spain, the estimated prevalence of hypertrophic cardiomyopathy was 0.24%. In the subgroup of patients with no hypertension, the estimated prevalence was 0.19%.